Meet the Evaluate Team: Christina Kay
Behind Evaluate’s data and insights about the biopharma space, there are people who work to make sure that our clients have everything they need to make their lives a little easier (at work, at least). In the latest of our Meet the Team blog series, we speak to Christina Kay, VP, Global Customer Success about […]
Medtech in 2028: Suffering or Celebrating a COVID Hangover?
We’ve extended our forecasts out to 2028 and in our latest report, we take a look at what’s in store for the medtech market in the next few years. It seems obvious to say that Covid had a massive impact on the medtech industry but being obvious doesn’t stop the statement being true. Several […]
Five Things You’re Getting Wrong in Your Pipeline Planning
R&D pipelines are the lifeblood of the pharma industry – so why are we still getting it wrong? More so than perhaps any other industry, the product pipeline is critical to pharma and biotech businesses. Long R&D timelines, regulatory hurdles, patent expirations and an ever-changing competitive landscape means that no company can afford to […]
Patient Centricity: The Unexpected Legacy of COVID-19
The world is a long way from understanding the true and far-reaching legacy of Covid-19. While debate regarding the handling of the pandemic will continue, there are areas where the impact has been more positive. Digital health tools and telehealth were already on the rise, but Covid-19 provided a catalyst, propelling innovation and adoption forward, […]
Demystifying AI: Natural Language Processing (Part Two)
Natural language processing (NLP) is a key component of many machine learning approaches. We’ve looked at (broadly) how it works, now we investigate some of they key use cases in the life sciences industry. In the first part of this blog post, we looked at how Natural Language Processing works (at a high level, of […]
Demystifying AI: Natural Language Processing (Part One)
Machine learning and artificial intelligence are increasingly-used buzzwords in the pharma and biotech space. But what’s hiding in that black box? Artificial intelligence (AI) seems to have found its way into almost every aspect of our lives. Depending on the application – or indeed on your point of view – this is anything from a […]
Biotech Investment in 2022 : “You’ve Got to Kiss a Lot of Frogs”
The market may be tough, but with unprecedented innovation taking place, there’s plenty for biotechs and investors to feel positive about in the long term. You may (or indeed may not) have seen our recent webinar, Tricky Terrain: Navigating the pharma investment landscape. If you did miss it, check it out to get a quick […]
BIO International 2022: Words From Space and Venus
Bio International was finally back for 2022. What did our first-timer to the event make of it? As a newcomer to the pharma and biotech industry, I was excited not only to be attending Bio International, but my first in-person convention in a while. It was a great feeling to be back on an exhibition […]
Biotech Terrain May Be Tricky, but It’s Worth Persevering
What are venture capitalists looking for from the biotech and pharma space? It is fair to say that the biotech market is having a challenging time. Much has been written about the lack of M&A activity, disappointing stock performances and the closing of the IPO window as those companies that have managed to get away […]
Five Reasons You Can’t Ignore Payers During Pipeline Development
Could previously launched drugs that significantly missed sales expectations have met a different fate if their manufacturers had accounted for payer perspectives in their early-stage development strategy? Let’s start with some stats. About half of the drugs launched in the last 15 years underperformed analysts’ sales estimates by more than 20%1. Only one-fifth of […]
